Mahesh Gopakumar retweetledi

What sets Brexpiprazole (Rexulti) apart as a third-generation antipsychotic?
Brexpiprazole is a partial dopamine D2 agonist classified as a serotonin-dopamine activity modulator (SDAM).
Its unique receptor profile offers a therapeutic edge by addressing:
✅ Positive symptoms (hallucinations, delusions).
✅ Negative symptoms (emotional withdrawal, lack of motivation).
✅ Cognitive deficits, an often-overlooked challenge in schizophrenia.
But how does Brexpiprazole achieve these outcomes? Let’s break it down 👇

English





















